By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Sequenom today with an Outperform rating, citing the commercial potential of the San Diego-based company's T21 molecular diagnostics test.

Analyst Brian Weinstein estimated in a research note that Sequenom would have 2011 revenues of $54.8 million and 2012 revenues of $78.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.